Allarity Therapeutics, Inc. Common Stock
$1.19
$0.07 (+6.76%)
$1.11Day Range$1.20
Key Statistics
Market Cap
$17.66M
Shares Outstanding
15.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Dec 21, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$1.13
Day High
$1.20
Day Low
$1.11
Volume
41.7K
VWAP
$1.15
Prev Close
$1.11
Transactions
--
Acc. Volume
--
About Allarity Therapeutics, Inc. Common Stock
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
PHARMACEUTICAL PREPARATIONSSIC 28348 employees24 SCHOOL ST., 2ND FLOOR, BOSTON, MA, 02108401-426-4664IPO Dec 21, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001860657
- Composite FIGI
- BBG012NXCZP8
- Share Class FIGI
- BBG012NXCZQ7
- Ticker Root
- ALLR
- SIC Code
- 2834
About Allarity Therapeutics, Inc. Common Stock (ALLR) Stock
Allarity Therapeutics, Inc. Common Stock (ALLR) closed the 2026-09-16 session at $1.19, up 6.76% versus the previous close (+0.07). The stock opened at $1.13 and traded between $1.11 and $1.20 during that session. Session trading volume was 42K shares. The volume-weighted average price (VWAP) is $1.15.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
Allarity Therapeutics, Inc. Common Stock has a market capitalization of $17.7 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ALLR is listed on the XNAS exchange. The company employs approximately 8 people. Allarity Therapeutics, Inc. Common Stock is headquartered in BOSTON, MA. The recorded listing date is 2021-12-21.
On this page you can find market ALLR stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.